Categories
Change Password!
Reset Password!
The efficacy of in vitro expanded
autologous BM-MSCs in improving functional outcomes of knee OA patients
supports the development of phase III clinical study.
Single intraarticular injection of in vitro expanded autologous bone-marrow mesenchymal stromal cells was found to be a safe and effective in providing long-term clinical and functional improvement in patients with knee osteoarthritis, as per a study published in the 'Journal of Translational Medicine'.
For knee OA treatment, MSCs prove to be capable enough. In
the past, many short-term clinical trials have been conducted to study the
safety and effectiveness of MSCs. However, there is lack of data evaluating long term outcomes of MSC in
OA patients. The authors investigated the
patients included in their previous randomized clinical trial to determine the
long-term clinical effect. The trial was carried out between
2012 and 2014. Thirty patients diagnosed with knee OA were randomly assigned to
Patients were followed up for one
year. VAS and WOMAC scorings were noted after
a follow up of 4 years. No adverse events were observed after the BM-MSCs administration or during the follow-up.
As per VAS, the BM-MSCs-administered patients showed reduction in pain. Clinical improvement was observed in the patients receiving BM-MSCs
according to the WOMAC scores. Increase in the median value
of 4 points (− 11; 10)
was observed in the control group while low-dose
and high-dose groups showed values of − 18 (− 28; − 9)
and − 10 (− 21; − 3) points, respectively. BM-MSCs receiving groups showed no considerable clinical differences.
Journal of Translational Medicine
Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)
Jose Maria Lamo-Espinosa et al.
Comments (0)